增殖细胞核抗原表达在恶性肿瘤监测中的应用

增殖细胞核抗原是一种与细胞增殖状态有关的核蛋白，已广泛用于肿瘤细胞增殖活性的研究，其过度表达与肿瘤细胞的生物学行为有关，其检测对乳腺癌、喉癌、食管癌、胃癌、肝癌、大肠癌、膀胱癌、子宫内膜癌和卵巢癌的诊断、疗效观察及预后监测有重要价值。     

听神经瘤TGF—β1的表达及其与肿瘤细胞增殖的相关性研究

目的探讨人听神经瘤中转化生长因子β1与肿瘤细胞增殖的相关性。方法应用免疫组织化学方法检测69例听神经瘤转化生长因子β1和增殖细胞核抗原的表达。分析转化生长因子β1与肿瘤细胞增殖指数之间的相关性。结果在实性组和复发组中，TGF—β1与PCNA指数有明显正相关，在囊变组中TGF-β1与PCNA指数无相关性。在以肿瘤直径为分组依据的各组听神经瘤之间，TGF—β1、PCNA的差异没有显著性，组内TGF—β1、PCNA之间无相关性。结论在实性和复发听神经瘤中，TGF-β1与肿瘤细胞增殖有一定关系，可作为预测肿瘤进展和复发的重要因子。     

听神经瘤TGF-β1的表达及其与肿瘤细胞增殖的相关性研究

目的探讨人听神经瘤中转化生长因子β1与肿瘤细胞增殖的相关性。方法应用免疫组织化学方法检测69例听神经瘤转化生长因子β1和增殖细胞核抗原的表达。分析转化生长因子β1与肿瘤细胞增殖指数之间的相关性。结果在实性组和复发组中,TGFβ1与PCNA指数有明显正相关,在囊变组中TGFβ1与PCNA指数无相关性。在以肿瘤直径为分组依据的各组听神经瘤之间,TGFβ1、PCNA的差异没有显著性,组内TGFβ1、PCNA之间无相关性。结论在实性和复发听神经瘤中,TGFβ1与肿瘤细胞增殖有一定关系,可作为预测肿瘤进展和复发的重要因子。     

增殖细胞核抗原在卵巢上皮性癌的表达及其临床意义

探讨增殖细胞核抗原表达与卵巢上皮性癌生物学行为及预后的关系。材料与方法：采用ＬＳＡＢ免疫组化方法检测８４例石蜡包埋的卵巢上皮性癌组织中增殖细胞核抗原的表达,分析其与患者的年龄、临床分期、组织分化程度、组织学类型及预后之间的关系。     

IGF-Ⅰ和IGF-ⅠR在膀胱癌组织中表达的意义

背景与目的:胰岛素样生长因子(insulin-like growth factors,IGFs)是一类具有促进细胞增殖、分化等多种生物学活性的多肽生长因子,研究表明其参与多种恶性肿瘤的发生、发展过程.本研究检测IGF-Ⅰ及其受体IGF-ⅠR和增殖细胞核抗原(proliferation cell nuclear antigen,PCNA)在正常膀胱组织和膀胱癌组织中的表达,评价IGF-Ⅰ和IGF-ⅠR的临床意义.方法:应用免疫组织化学方法检测IGF-Ⅰ、IGF-ⅠR和PCNA在88例膀胱癌和12例正常膀胱组织中的表达,同时对IGF-Ⅰ和IGF-ⅠR表达与膀胱癌病理分级、临床分期、预后及PCNA表达之间的关系进行分析.结果:膀胱癌组织中IGF-Ⅰ和IGF-ⅠR阳性率分别为73.9%、59.1%,均显著高于正常膀胱组织的33.3%、16.7%(P＜0.05).膀胱癌中两者呈相关表达且均与PCNA指数密切相关(P＜0.05).IGF-Ⅰ表达与肿瘤复发之间关系密切(P＜0.05),IGF-ⅠR表达则与肿瘤分级、分期和复发关系密切(P＜0.05).结论:IGF-Ⅰ与肿瘤复发有关,IGF-ⅠR表达与肿瘤分级、分期和复发有关.     

IGF-Ⅰ和IGF-ⅠR在膀胱癌组织中表达的意义

背景与目的:胰岛素样生长因子(insulin-likegrowthfactors,IGFs)是一类具有促进细胞增殖、分化等多种生物学活性的多肽生长因子,研究表明其参与多种恶性肿瘤的发生、发展过程。本研究检测IGF-Ⅰ及其受体IGF-ⅠR和增殖细胞核抗原(proliferationcellnuclearantigen,PCNA)在正常膀胱组织和膀胱癌组织中的表达,评价IGF-Ⅰ和IGF-ⅠR的临床意义。方法:应用免疫组织化学方法检测IGF-Ⅰ、IGF-ⅠR和PCNA在88例膀胱癌和12例正常膀胱组织中的表达,同时对IGF-Ⅰ和IGF-ⅠR表达与膀胱癌病理分级、临床分期、预后及PCNA表达之间的关系进行分析。结果:膀胱癌组织中IGF-Ⅰ和IGF-ⅠR阳性率分别为73.9%、59.1%,均显著高于正常膀胱组织的33.3%、16.7%(P<0.05)。膀胱癌中两者呈相关表达且均与PCNA指数密切相关(P<0.05)。IGF-Ⅰ表达与肿瘤复发之间关系密切(P<0.05),IGF-ⅠR表达则与肿瘤分级、分期和复发关系密切(P<0.05)。结论:IGF-Ⅰ与肿瘤复发有关,IGF-ⅠR表达与肿瘤分级、分期和复发有关。     

bFGF及其抗体对裸鼠皮下移植膀胱癌生长影响的研究

 目的　探讨碱性成纤维细胞生长因子 (bFGF)及其抗体对裸鼠人膀胱癌移植瘤生长的影响和作用机制。方法　建立膀胱癌EJ细胞裸鼠皮下移植瘤动物模型 ,观察bFGF和bFGF抗体对裸鼠皮下瘤生长状况的影响 ;应用免疫组织化学方法检测肿瘤组织中增殖细胞核抗原 (PCNA)和Ⅷ因子相关抗原的表达。结果　 (1)bFGF治疗组皮下瘤体积和重量分别比对照组显著增多 ,瘤组织中PCNA指数和微血管密度 (MVD)也显著提高 ;(2 )bFGF抗体治疗组皮下瘤体积和重量比对照组均显著减少 ,瘤组织中PC NA指数和MVD也显著降低。结论　bFGF能够促进膀胱癌生长而bFGF抗体具有抑制肿瘤的作用 ,其作用机制与调控肿瘤细胞增殖和血管形成有关     

增植细胞核抗原在胃粘膜不典型增生中的表达及其意义

近年来,许多学者将细胞增殖活性与肿瘤的发生、预后等生物学行为联系起来研究。其中,增殖细胞核抗原/周期素(Proliferating cell nuclear antigen/Cyclin)在肿瘤细胞动力学及细胞增殖活性方面的研究日益活跃,而有关胃粘膜癌前病变中PCNA的研究国内尚     

胰腺癌组织增殖细胞核抗原的测定及其临床意义

目的　研究胰腺癌组织中增殖细胞核抗原 (PCNA)的表达与临床生物学行为之间的关系。方法　应用免疫组织化学ABC法对 39例存档胰腺癌标本和 8例慢性胰腺炎标本进行PCNA的定量分析。结果　 39例胰腺癌组织中PCNA增殖指数 (LI)为 2 7 5 4± 16 42 ,而 8例胰腺炎组织中未发现有PCNA的阳性表达 ,PCAN增殖指数与患者的年龄、性别及肿瘤的部位无关 (P >0 0 5 ) ,而与肿瘤的大小、组织学分级、临床分期及淋巴结转移密切相关。结论　PCNA是反映胰腺癌生物学行为和预后的重要指标 ,高表达提示肿瘤的恶性程度高 ,预后不良。     

PCNA在宫颈鳞癌中的表达及其临床意义

目的　探讨PCNA基因过度表达在子宫颈上皮内瘤变(CIN)及子宫颈鳞形细胞癌中的意义。方法　标本采用常规石蜡切片、HE染色及ABC法免疫组化染色,光镜观察,并对增殖细胞核抗原指数(PCNALI)进行计数。结果　从正常宫颈鳞状上皮到CINⅡ级到子宫颈鳞癌,表达PCNA阳性的细胞范围和阳性强度呈明显增高的趋势,三者间PCNALI差异有显著性(P<001)。在45例鳞状细胞癌中PCNALI随着肿瘤分级增高而增高。鳞癌Ⅰ级、Ⅱ级和Ⅲ级之间PCNALI差异有显著性(P<005)。局部淋巴结有转移癌者和无转移癌者PCNALI差异亦有显著性(P<005)。结论　PCNALI对于检测宫颈鳞癌的发生与发展、早期诊断及判断肿瘤的生物学行为和预测患者的预后等方面具有重要的意义。     

泌尿系移行细胞癌c-erbB-2基因蛋白和PCNA的表达及意义

为探讨ｃ－ｅｒｂＢ－２基因蛋白和ＰＣＮＡ在膀胱癌及肾盂癌中的表达及意义。作者应用免疫组化技术研究４７例膀胱移行细胞癌和１８例肾盂移行细胞癌与ｃ－ｅｒｂＢ－２基因蛋白和ＰＣＮＡ的关系。结果显示ｃ－ｅｒｂＢ－２蛋白表达与膀胱癌和肾盂癌的分级和分期有关，ＰＣＮＡ增殖指数随肿瘤分级的上升而增高，与肿瘤的分期也有关系，但ｃ－ｅｒｂＢ－２和ＰＣＮＡ两者间无明显关系。结果表明ｃ－ｅｒｂＢ－２和ＰＣＮＡ对膀胱癌和肾盂癌的生物学行为和预后评估具有重要意义。     

膀胱癌PCNA蛋白表达及其与复发的关系

[目的]探讨增殖细胞核抗原（proliferating cell nuclear antigen,PCNA）蛋白在膀胱癌中的表达情况,并分析其与临床病理特征及复发的关系。[方法]148例膀胱移行细胞癌患者标本,25例癌旁正常组织标本作为对照,采用免疫组化SP法检测PCNA蛋白的表达。[结果]癌旁正常组织中PCNA蛋白的阳性表达水平明显低于肿瘤组织（16.0%vs50.7%,P〈0.001）。PCNA蛋白的表达与膀胱癌的分级、分期、复发有关（P〈0.05）,与患者的年龄、性别、肿瘤数目及肿瘤大小无关（P〉0.05）。本组104例浅表性膀胱癌（Ta～T1）随访2～95个月,其中复发64例,复发组与未复发组PCNA蛋白的阳性表达率分别为56.3%和15.0%（P=0.001）。[结论]PCNA蛋白在膀胱癌中高表达,其高表达提示预后不良。     

卵巢粒层细胞瘤中PCNA表达及血管发生的意义

用免疫组化ＡＢＣ方法检测了３５例卵巢粒层细胞瘤瘤细胞增生细胞核抗原（ＰＣＮＡ）的表达和瘤组织中血管形成的情况。结果表明：ＰＣＮＡ的阳性率在２８例存活５年以上与７例存活少于５年的两组病例中存在非常显著的差别（Ｐ＜０．０１），其阳性表达并与肿瘤的临床分期密切相关（Ｐ＜０．０１）。而肿瘤组织中微血管数在该两组病例中无显著差别，与肿瘤的临床分期亦无关系。作者认为，在卵巢粒层细胞瘤中检测ＰＣＮＡ的表达有助于了解它们的生物学行为并有辅助预测预后的价值，而肿瘤中的血管形成并非决定该类肿瘤生物学行为的一个重要因素     

Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression

Meningiomas are principally benign in nature. Some meningiomas, however, grow fast or recur even after total removal. The biological behavior of meningiomas often can not be predicted from conventional histopathological studies. A monoclonal antibody against proliferating cell nuclear antigen (PCNA) was used to investigate the usefulness of the PCNA index as a parameter to estimate the proliferative activity of meningiomas. Fifty-two meningiomas were examined. The mean PCNA index of recurrent meningiomas (3.37±0.92%) was significantly higher than that of non-recurrent meningiomas (1.12±0.51%) (p <0.005). The PCNA indices of recurrent cases were all higher than 2.0%. A semilog linear regression analysis between tumor doubling time and PCNA index showed a significant correlation (r=0.90, p < 0.05). An inverse linear correlation between PCNA index and interval to recurrence was observed (r=0.62, p < 0.05). A good linear correlation was also shown between PCNA index and BUdR labeling index (r = 0.88, p < 0.01). The results of this study suggest that, providing the methods of tissue processing, immunostaining and counting of positive nuclei are unified, the PCNA index is a useful parameter for estimating the biological behavior of meningiomas.     

膀胱移行细胞癌树突状细胞浸润和PCNA表达的临床病理研究

目的　探讨膀胱移行细胞癌组织中树突状细胞 (DCs)浸润和PCNA的表达与临床病理特征的关系。方法　采用免疫组织化学SP法检测 3 1例膀胱移行细胞癌术后组织标本中增殖细胞核抗原 (PCNA )以及DCs标志蛋白S 10 0的表达。结果　不同病理分级及临床分期以及单发癌灶与多发癌灶的膀胱移行细胞癌 ,其DCs数量相互比较 ,均有显著性差异 (P <0 .0 5 ) ;原发与复发膀胱癌的DCs浸润数无显著性差异 (P >0 .0 5 )。不同病理分级膀胱移行细胞癌PCNA阳性表达细胞数比较有显著性差异 (P<0 .0 5 )。结论　膀胱癌DCs浸润数量随病理分级、临床分级的升高而降低 ,而PCNA随病理分级的升高而增高。DC可以作为预测膀胱癌生物行为的指标之一     

The value of cell proliferation and angiogenesis in the prognostic assessment of ovarian granulosa cell tumors.

OBJECTIVES: Most cases of granulosa cell tumors (GCT) of the ovary are characterized by a relatively good outcome. However, some tumors behave aggressively and some tend to recur many years after the initial diagnosis. Tumor growth depends on cell proliferation and angiogenesis. Thus, proliferative indices and microvessel density were studied to determine possible valuable methods to assess the GCT patient's outcome. METHODS and study design: Paraffin-embedded tissue blocks were available for 60 patients with primary GCT and were investigated by immunostaining with monoclonal antibodies against PCNA, Ki-67 and factor VIII-related antigen. The follow-up was available for 51 patients and ranged from 25 to 206 months. A clinical follow-up distribution of patients was made: 8 patients with recurrence (group I); 6 patients who lived with no evidence of recurrence for 100 months or more (group II), and 37 patients alive with no evidence of recurrence in the follow-up period of less than 100 months (group III). RESULTS: There was a statistical correlation between PCNA and Ki-67 proliferative indices. A significant increase (P <0.05) of mean PCNA and Ki-67 proliferative indices and mean tumor size was seen in patients of Group I compared to those of Group II. The mean PCNA proliferative index positively correlated with the mean Ki-67 proliferative index for Groups I and II. Mean microvessel density showed a positive correlation with mean PCNA and Ki-67 proliferative indices and with mean tumor size for Group I, whereas it was negatively correlated with PCNA proliferative index and tumor size for Group II. A positive correlation was found between mean mitotic count and both proliferative indices only for Group II. The following features were indicative of a relatively poor prognosis: GCT measuring >9 cm in diameter, PCNA >4.0%, Ki-67 >1.2%, and diffuse, insular and sarcomatoid histologic patterns. CONCLUSIONS: The findings support the importance of proliferative factors, tumor size and histologic patterns as possible prognostic indicators for estimating the biologic behavior of patients with GCT. Unfortunately, angiogenesis did not seem to be a useful determinant parameter of a possible aggressive behavior. However, a longer follow-up period with larger series may be required to assess the value of the parameters in prediction of patient survival.     

膀胱移行细胞癌增殖细胞核抗原与肿瘤间质微血管密度的表达与临床及预后的意义

目的：探讨膀胱移行细胞癌组织中增殖细胞核抗原（ＰＣＮＡ）与肿瘤间质微血管密度（ＭＶＤ）的表达及其临床与预后的意义。方法：对７２例膀胱移行细胞癌进行ＰＣＮＡ及第Ⅷ因子相关抗原（ＶＷＦＬ：Ａｇ）单克隆抗体免疫组化染色。结果：ＰＣＮＡ增殖指数与肿瘤间质微血管密度之间存在正相关性,二者的表达皆与膀胱移行细胞癌的病理分级显著相关,１级与２级、２级与３级之间存在显著性差异（Ｐ〈０．０１）,侵袭性肿瘤明显高于线     

膀胱移行细胞癌中p53突变、bcl-2和PCNA表达的临床意义(英文)

目的探讨膀胱癌中 bcl-2、p53、PCNA 表达与细胞增殖、凋亡和临床病理学参数之间的关系。方法 SABC 免疫组化分折62例(T1G1-G339例,T2-T4aG3 NOM023例)甲醛固定和石蜡包埋的膀胱癌标本 bcl-2、p53和 PCNA 蛋白的免疫反应性。平均随访37个月,24例复发。增殖指数(PI)表示肿瘤细胞中 PCNA 阳性细胞百分比。TUNEL 法检测细胞凋亡,凋亡指数(AI)表示肿瘤细胞中凋亡细胞的百分比。结果 62例膀胱癌中,50例(80.0%)发生 p53突变,与 G1(72.7%)和 G2(78.5%)相比较 G3(91.3%)更多见(P<0.05);pT2期(95.7%)p53突变率较 pTa-1期(74.3%)高(P<0.01)。14例(22.5%)发现有 bcl-2表达,bcl-2表达阳性率 G3明显高于 G1和 G2(P<0.05),与分期无关(P>0.05)。Bcl-2表达与 p53突变无关。在膀胱癌中,PI 为17.2%～41.8%(平均为22.4%),AI 为1.9%～3.5%(平均为2.9%)。统计分析显示 PI 与肿瘤分级、分期关系密切,AI 与肿瘤的分级有明显关系。结论结果表明,p53突变与浸润性行为呈正相关。在膀胱癌中 p53和 PCNA 过表达可能能提供有价值的预后信息。随着肿瘤的进展,肿瘤细胞过度增殖可能伴有频繁的凋亡,但增殖指数的增加明显强于凋亡指数的增加。     

膀胱移行细胞癌中p53突变、bcl-2和PCNA表达的临床意义

To correlate the frequency of p53 mutations, bcl-2 expression and the proliferation status (proliferating cell nuclear antigen, PCNA) in patients with bladder cancer with cell proliferation, apoptosis and their clinico-pathologic findings. Paraffin-embedded sections from 39 superficial (T1G1-G3) and 23 invasive (T2-T4a G3 N0M0) primary transitional cell carcinomas (TCC) in the bladder were investigated immunohistochemically for p53, bcl-2 and PCNA. The median follow-up was 37 months; 24 had recurrences. The proliferation index (PI) was expressed as a percentage of the PCNA-positive cells in the tumor cells. Apoptosis was detected by terminal deoxy-nucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), and the apoptotic index (AI) was expressed as a percentage of the TUNEL-positive tumor cells. p53 mutation was identified in 50 patients (80.6%). The mutation was most common in tumors grade 3 (91.3%) as compared to grade 2 (78.5%) and grade 1 (72.7%, P<0.05). Stage pT2 tumors had a higher frequency of p53 mutation (95.7%) as compared to pTa-1 tumors (74.3%, P<0.01). Only 14 tumors (22.5%) expressed bcl-2; grade 3 tumors expressed bcl-2 significantly more frequently (P<0.05); there was no correlation between bcl-2 and tumor stage. There was no interrelation between p53 mutation and bcl-2 expression (P>0.05). The PI ranged from 17.2% to 41.8% (median 22.4%) and the AI from 1.9% to 3.5% (median 2.9%) in bladder cancer. Statistical analyses revealed a close associations between PI, AI and tumor grade and stage of bladder cancer. p53 mutation correlates with invasion. p53 and PCNA overexpression may offer valuable additional prognostic information in bladder tumors. With the progression of the tumor grade, cell proliferation may be accompanied by frequent apoptosis in bladder cancer, but the PI increased much more than the AI.